References
- Alnemri ES, Livingston DJ, Nicholson DW, Salvesen G, Thornberry NA, Wong WW, Yuan J. Human ICE/CED-3 protease nomenclature. Cell 1996. 87: 171. https://doi.org/10.1016/S0092-8674(00)81334-3
- Cha JY, Cho TI, Park TY, So JS, Choi SK, Park ES. Analysis of expression of survivin, caspase 3, and p53 protein in cervical neoplasia comparing with ki-67 index. Korean J Gynecol Oncol. 2008.19: 17-25. https://doi.org/10.3802/kjgo.2008.19.1.17
- Chang F, Syrjanen S, Kurvinen K, Sytjanen K. The p53 tumor suppressor gene as a common cellular target in human carcinogenesis. Am J Gastroenterol. 1993. 88: 174-186.
- Haldar S, Negrini M, Monne M, Sabbioni S, Croce CM. Down-regulation of bcl-2 by p53 in breast cancer cells. Cancer Res. 1994. 54: 2095-2097.
- Hall PA, Lane DP. p53 in tumour pathology: can we trust immunohistochemistry? J Pathol. 1994. 172: 14.
- Hoshi T, Sasano H, Kato K, Yabuki N, Ohara S, Konno R, Asaki S, Toyota T, Tateno H, Nagura H. Immunohistochemistry of Caspase3/CPP32 in human stomach and its correlation with cell proliferation and apoptosis. Am J Pathol. 1997. 151: 821-829.
- Hsia JY, Chen CY, Chen JT, Hsu CP, Shai SE, Yang SS, Chuang CY, Wang PY, Miaw J. Prognostic significance of caspase-3 expression in primary resected esophageal squamous cell carcinoma. Eur J Surg Oncol. 2003. 29: 4448.
- Kluck RM, Bossy-Wetzel E, Green DR, Newmeyer DD. The release of cytochrome c from mitochondria: a primary site for Bcl-2 regulation of apoptosis. Science 1997. 275: 1132-1136. https://doi.org/10.1126/science.275.5303.1132
- Janicke RU, Sprengart ML, Wati MR, Porter AG. Caspase-3 is required for DNA fragmentation and morphological changes associated with apoptosis. J Biol Chem. 1998. 273: 9357-9360. https://doi.org/10.1074/jbc.273.16.9357
- Li YH, Wang C, Meng K, Chen LB, Zhou XJ. Influence of survivin and caspase-3 on cell apoptosis and prognosis in gastric carcinoma. World J Gastroenterol. 2004. 10: 1984-1988.
- Miraz A, McGuirk M, Hockenbery TN, Wu Q, Ashar H, Black S. Human surviving is negatively regulated by wild type p53 and participates in p53 dependant apoptotic pathway. Oncogene 2002. 21: 2613-2622. https://doi.org/10.1038/sj.onc.1205353
- Montironi R, Galluzzi CM, Fabris G. Apoptotic bodies in prostate intra-epithelial neoplasia and prostatic adenocarcinoma following total androgen ablation. Pathol Res Pract. 1995. 191: 873-880. https://doi.org/10.1016/S0344-0338(11)80971-4
- Izban KF, Wrone-Smith T, Hsi ED, Schnitzer B, Quevedo ME, Alkan S. Characterization of the interleukin-1 beta-converting enzyme/ced-3-family protease, caspase-3/CPP32, in Hodgkin's disease: lack of caspase-3 expression in nodular lymphocyte predominance Hodgkin's disease. Am J Pathol. 1999 154: 1439-1447. https://doi.org/10.1016/S0002-9440(10)65398-9
- Sohn JH, Kim DH, Choi NG, Park YE, Ro JY. Caspase-3/CPP32 immunoreactivity and its correlation with frequency of apoptotic bodies in human prostatic carcinomas and benign nodular hyperplasias. Histopathology 2000. 37: 555-560. https://doi.org/10.1046/j.1365-2559.2000.01062.x
- Steven GS, Ronald AD. Principles and practice of surgical pathology and cytopathology. 3rd ed. Baltimore: Churchill Livingstone 1997. 2492-2494.
- Vakkala M, Paakko P, Soini Y. Expression of caspases 3, 6 and 8 is increased in parallel with apoptosis and histological aggressiveness of the breast lesion. Br J Cancer. 1999. 81: 592-599. https://doi.org/10.1038/sj.bjc.6690735